Alvaro NA Monteiro, PhD

Where You Are:
Alvaro NA Monteiro, PhD

Senior Member

Office  (813) 745-6321

Education And Training
  • Postdoctoral Fellow, The Rockefeller University, 1998 - Molecular Oncology
  • PhD, Federal University of Rio de Janeiro, 1992 - Biochemistry
  • MSc, Federal University of Rio de Janeiro, 1988 - Biochemistry
  • BSc, Federal University of Rio de Janeiro, 1985 - Genetics


The goal of Dr. Monteiro and his laboratory colleagues is to elucidate the role of genes involved in the development of breast and ovarian cancer. Their primary focus is on the function of the tumor suppressor geneBRCA1. Hereditary breast and ovarian cancers represent approximately 5% of all cases, and inherited mutations in BRCA1 account for the majority of familial breast and ovarian cancers. The human BRCA1 gene codes for a nuclear phosphoprotein that is likely to be multifunctional. Recent genetic and biochemical evidence points to the involvement of BRCA1 in two fundamental processes: DNA damage response and transcriptional regulation. The researchers' immediate goals are two-fold: to dissect the BRCA1 biochemical pathway and determine its precise biochemical function and to develop a functional assay to provide more reliable information for risk assessment in individuals carrying germline mutations in BRCA1.

In pursuit of these goals, Dr. Monteiro and his colleagues have used temperature-sensitive alleles to dissect the role of BRCA1 in DNA damage response. BRCA1 has been implicated in a variety of DNA repair processes, yet none of the evidence indicates a potential biological mechanism by which BRCA1 may act. The researchers recently discovered a cancer-predisposing allele of BRCA1 that displays temperature-sensitive (TS) activity in transcription. Utilizing their expertise in mutagenesis screening in yeast, they isolated ten additional unique TS mutants of BRCA1, which are currently being analyzed. Conditional mutants such as these are valuable research tools to dissect biochemical pathways, and Dr. Monteiro believes that these reagents will provide a direct approach to determine the precise function of BRCA1.

One of the most pressing problems in risk assessment for individuals carrying mutations in BRCA1 is the dearth of information regarding the cancer association of hundreds of missense mutations found in the population (unclassified variants). These alleles are usually very rare and, in some cases, specific to one ethnic group, making meaningful population-based studies extremelydifficult. Unless the particular mutations have been classified by case-control studies, linkage, or segregation analysis as benign polymorphisms or cancer-predisposing mutations, there is no predictive value in the diagnostics. One alternative is to devise functional assays to classify these variants. During the past 5 years, Dr. Monteiro and his colleagues have made significant progress toward development of a functional assay for BRCA1 based on its transcription activation activity. Most importantly, they have been able to validate their findings by coupling population-based data to their functional assay. Their efforts to understand the outcome of all missense mutations in BRCA1 led them to a collaborative effort to predict the outcome of these mutations in the BRCA1 C-terminus (BRCT) by using structural modeling. Because they believe that a comprehensive functional analysis will be needed to provide information for risk assessment, they are now embarking on a multicenter interdisciplinary effort to comprehensively classify BRCA1 alleles.

In summary, the strategy of Dr. Monteiro and his colleagues is to approach breast and ovarian cancer from different perspectives by studying its fundamental aspects and to develop applied methodology to rapidly translate their knowledge into useful information for patients and clinicians.

  • Carvalho RS, Fernandes VC, Nepomuceno TC, Rodrigues DC, Woods NT, Suarez-Kurtz G, Chammas R, Monteiro AN, Carvalho MA. Characterization of LGALS3 (galectin-3) as a player in DNA damage response. Cancer Biol Ther. 2014 Jul;15(7):840-850. Pubmedid: 24755837.
  • Cragun D, Camperlengo L, Robinson E, Caldwell M, Kim J, Phelan C, Monteiro AN, Vadaparampil ST, Sellers TA, Pal T. Differences in BRCA counseling and testing practices based on ordering provider type. Genet Med. 2014 Jun. Pubmedid: 24922460.
  • Iversen ES, Lipton G, Clyde MA, Monteiro AN. Functional annotation signatures of disease susceptibility loci improve SNP association analysis. BMC Genomics. 2014 Jun;15:398. Pubmedid: 24886216.
  • Egan KM, Baskin R, Nabors LB, Thompson RC, Olson JJ, Browning JE, Madden MH, Monteiro AN. Brain tumor risk according to germ-line variation in the MLLT10 locus. Eur J Hum Genet. 2014 Apr. Pubmedid: 24755950.
  • Guidugli L, Carreira A, Caputo SM, Ehlen A, Galli A, Monteiro AN, Neuhausen SL, Hansen TV, Couch FJ, Vreeswijk MP. Functional assays for analysis of variants of uncertain significance in BRCA2. Hum Mutat. 2014 Feb;35(2):151-164. Pubmedid: 24323938. Pmcid: PMC3995136.
  • Pal T, Lee JH, Besharat A, Thompson Z, Monteiro A, Phelan C, Lancaster J, Metcalfe K, Sellers T, Vadaparampil S, Narod S. Modes of delivery of genetic testing services and the uptake of cancer risk management strategies in BRCA1 and BRCA2 carriers. Clin Genet. 2014 Jan;85(1):49-53. Pubmedid: 23438721.
  • Madden MH, Anic GM, Thompson RC, Nabors LB, Olson JJ, Browning JE, Monteiro AN, Egan KM. Circadian pathway genes in relation to glioma risk and outcome. Cancer Causes Control. 2014 Jan;25(1):25-32. Pubmedid: 24135790.
  • Carvalho RS, Abreu RB, Velkova A, Marsillac S, Rodarte RS, Suarez-Kurtz G, Iversen ES, Monteiro AN, Carvalho MA. Probing Structure-Function Relationships in Missense Variants in the Carboxy-Terminal Region of BRCA1. PLoS One. 2014;9(5):e97766. Pubmedid: 24845084.
  • Monteiro AN, Freedman ML. Lessons from postgenome-wide association studies: functional analysis of cancer predisposition loci. J Intern Med. 2013 Nov;274(5):414-424. Pubmedid: 24127939. Pmcid: PMC3801430.
  • Pal T, Bonner D, Kim J, Monteiro AN, Kessler L, Royer R, Narod SA, Vadaparampil ST. Early onset breast cancer in a registry-based sample of African-american women: BRCA mutation prevalence, and other personal and system-level clinical characteristics. Breast J. 2013 Sep;19(2):189-192. Pubmedid: 23320992.
  • Tulchin N, Ornstein L, Dikman S, Strauchen J, Jaffer S, Nagi C, Bleiweiss I, Kornreich R, Edelmann L, Brown K, Bodian C, Nair VD, Chambon M, Woods NT, Monteiro AN. Localization of BRCA1 protein in breast cancer tissue and cell lines with mutations. Cancer Cell Int. 2013 Jul;13(1):70. Pubmedid: 23855721. Pmcid: PMC3720266.
  • Domchek SM, Tang J, Stopfer J, Lilli DR, Hamel N, Tischkowitz M, Monteiro AN, Messick TE, Powers J, Yonker A, Couch FJ, Goldgar DE, Davidson HR, Nathanson KL, Foulkes WD, Greenberg RA. Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer. Cancer Discov. 2013 Apr;3(4):399-405. Pubmedid: 23269703. Pmcid: PMC3625496.
  • Woods NT, Mesquita RD, Sweet M, Carvalho MA, Li X, Liu Y, Nguyen H, Thomas CE, Iversen ES, Marsillac S, Karchin R, Koomen J, Monteiro AN. Charting the landscape of tandem BRCT domain-mediated protein interactions. Sci Signal. 2013 Feb;5(242):rs6. Pubmedid: 22990118. Pmcid: PMC4064718.
  • Egan KM, Nabors LB, Olson JJ, Monteiro AN, Browning JE, Madden MH, Thompson RC. Rare TP53 genetic variant associated with glioma risk and outcome. J Med Genet. 2013 Jan;49(7):420-421. Pubmedid: 22706378. Pmcid: PMC3576847.
  • Quiles F, Fernández-Rodríguez J, Mosca R, Feliubadaló L, Tornero E, Brunet J, Blanco I, Capellá G, Pujana MÀ, Aloy P, Monteiro A, Lázaro C. Functional and Structural Analysis of C-Terminal BRCA1 Missense Variants. PLoS One. 2013;8(4):e61302. Pubmedid: 23613828.
  • Millot GA, Carvalho MA, Caputo SM, Vreeswijk MP, Brown MA, Webb M, Rouleau E, Neuhausen SL, Hansen Tv, Galli A, Brandão RD, Blok MJ, Velkova A, Couch FJ, Monteiro AN. A guide for functional analysis of BRCA1 variants of uncertain significance. Hum Mutat. 2012 Nov;33(11):1526-1537. Pubmedid: 22753008. Pmcid: PMC3470782.
  • Gerloff DL, Woods NT, Farago AA, Monteiro AN. BRCT domains: A little more than kin, and less than kind. FEBS Lett. 2012 Aug;586(17):2711-2716. Pubmedid: 22584059. Pmcid: PMC3413754.
  • Velkova A, Monteiro AN. CHEKing out of mitosis. Cell Cycle. 2012 May;11(9):1756. Pubmedid: 22510558.
  • Lindor NM, Guidugli L, Wang X, Vallée MP, Monteiro AN, Tavtigian S, Goldgar DE, Couch FJ. A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS). Hum Mutat. 2012 Jan;33(1):8-21. Pubmedid: 21990134. Pmcid: PMC3242438.
  • Liu Y, Woods NT, Kim D, Sweet M, Monteiro AN, Karchin R. Yeast two-hybrid junk sequences contain selected linear motifs. Nucleic Acids Res. 2012 Jan;39(19):e128. Pubmedid: 21785140. Pmcid: PMC3201885.
  • Spurdle AB, Healey S, Devereau A, Hogervorst FB, Monteiro AN, Nathanson KL, Radice P, Stoppa-Lyonnet D, Tavtigian S, Wappenschmidt B, Couch FJ, Goldgar DE. ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes. Hum Mutat. 2012 Jan;33(1):2-7. Pubmedid: 21990146. Pmcid: PMC3240687.
  • Velkova A, Monteiro AN. Epigenetic tumor suppression by BRCA1. Nat Med. 2011 Oct;17(10):1183-1185. Pubmedid: 21988990.
  • Freeman AK, Monteiro AN. Phosphatases in the cellular response to DNA damage. Cell Commun Signal. 2011 Jul;8:27. Pubmedid: 20860841. Pmcid: PMC2954851.
  • Permuth-Wey J, Kim D, Tsai YY, Lin HY, Chen YA, Barnholtz-Sloan J, Birrer MJ, Bloom G, Chanock SJ, Chen Z, Cramer DW, Cunningham JM, Dagne G, Ebbert-Syfrett J, Fenstermacher D, Fridley BL, Garcia-Closas M, Gayther SA, Ge W, Gentry-Maharaj A, Gonzalez-Bosquet J, Goode EL, Iversen E, Jim H, Kong W, McLaughlin J, Menon U, Monteiro AN, Narod SA, Pharoah PD, Phelan CM, Qu X, Ramus SJ, Risch H, Schildkraut JM, Song H, Stockwell H, Sutphen R, Terry KL, Tyrer J, Vierkant RA, Wentzensen N, Lancaster JM, Cheng JQ, Sellers TA. LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer. Cancer Res. 2011 Jun;71(11):3896-3903. Pubmedid: 21482675. Pmcid: PMC3107389.
  • Freedman ML, Monteiro AN, Gayther SA, Coetzee GA, Risch A, Plass C, Casey G, De Biasi M, Carlson C, Duggan D, James M, Liu P, Tichelaar JW, Vikis HG, You M, Mills IG. Principles for the post-GWAS functional characterization of cancer risk loci. Nat Genetics. 2011 Jun;43(6):513-518. Pubmedid: 21614091. Pmcid: PMC3325768.
  • Iversen ES, Couch FJ, Goldgar DE, Tavtigian SV, Monteiro AN. A computational method to classify variants of uncertain significance using functional assay data with application to BRCA1. Cancer Epidemiol Biomarkers Prev. 2011 Jun;20(6):1078-1088. Pubmedid: 21447777. Pmcid: PMC3111818.
  • Mesquita RD, Woods NT, Seabra-Junior ES, Monteiro AN. Tandem BRCT Domains: DNA's Praetorian Guard. Genes Cancer. 2010 Nov;1(11):1140-1146. Pubmedid: 21533002. Pmcid: PMC3082952.
  • Price M, Monteiro AN. Fine tuning chemotherapy to match BRCA1 status. Biochem Pharmacol. 2010 Sep;80(5):647-653. Pubmedid: 20510205. Pmcid: PMC2925507.
  • Lee MS, Green R, Marsillac SM, Coquelle N, Williams RS, Yeung T, Foo D, Hau DD, Hui B, Monteiro AN, Glover JN. Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays. Cancer Res. 2010 Jun;70(12):4880-4890. Pubmedid: 20516115. Pmcid: PMC3040717.
  • Velkova A, Carvalho MA, Johnson JO, Tavtigian SV, Monteiro AN. Identification of Filamin A as a BRCA1-interacting protein required for efficient DNA repair. Cell Cycle. 2010 Apr;9(7):1421-1433. Pubmedid: 20305393. Pmcid: PMC3040726.
  • Rios-Doria J, Meléndez J, Monteiro AN. Three-color intranuclear staining for measuring mitosis and apoptosis in cells transfected with a GFP-tagged histone. Biotech Histochem. 2010 Apr;85(2):127-131. Pubmedid: 19657782.
  • Tulchin N, Chambon M, Juan G, Dikman S, Strauchen J, Ornstein L, Billack B, Woods NT, Monteiro AN. BRCA1 protein and nucleolin colocalize in breast carcinoma tissue and cancer cell lines. Am J Pathol. 2010 Mar;176(3):1203-1214. Pubmedid: 20075200. Pmcid: PMC2832143.
  • Freeman AK, Dapic V, Monteiro AN. Negative regulation of CHK2 activity by protein phosphatase 2A is modulated by DNA damage. Cell Cycle. 2010 Feb;9(4):736-747. Pubmedid: 20160490. Pmcid: PMC3040716.
  • Metro G, Zheng Z, Fabi A, Schell M, Antoniani B, Mottolese M, Monteiro AN, Vici P, Lara Rivera S, Boulware D, Cognetti F, Bepler G. In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy. Cancer Invest. 2010 Feb;28(2):172-180. Pubmedid: 19968494. Pmcid: PMC3565222.
  • De Ligio JT, Velkova A, Zorio DA, Monteiro AN. Can the status of the breast and ovarian cancer susceptibility gene 1 product (BRCA1) predict response to taxane-based cancer therapy?. Anticancer Agents Med Chem. 2009 Jun;9(5):543-549. Pubmedid: 19519295. Pmcid: PMC2745270.
  • Yamaguchi H, Woods NT, Piluso LG, Lee HH, Chen J, Bhalla KN, Monteiro A, Liu X, Hung MC, Wang HG. p53 acetylation is crucial for its transcription-independent proapoptotic functions. J Biol Chem. 2009 Apr;284(17):11171-11183. Pubmedid: 19265193. Pmcid: PMC2670122.
  • Rios-Doria J, Velkova A, Dapic V, Galán-Caridad JM, Dapic V, Carvalho MA, Melendez J, Monteiro AN. Ectopic expression of histone H2AX mutants reveals a role for its post-translational modifications. Cancer Biol Ther. 2009 Mar;8(5):422-434. Pubmedid: 19305155.
  • Carvalho M, Pino MA, Karchin R, Beddor J, Godinho-Netto M, Mesquita RD, Rodarte RS, Vaz DC, Monteiro VA, Manoukian S, Colombo M, Ripamonti CB, Rosenquist R, Suthers G, Borg A, Radice P, Grist SA, Monteiro AN, Billack B. Analysis of a set of missense, frameshift, and in-frame deletion variants of BRCA1. Mutat Res-Fund Mol M. 2009 Jan;660(1-2):1-11. Pubmedid: 18992264. Pmcid: PMC2682550.
  • Couch FJ, Rasmussen LJ, Hofstra R, Monteiro AN, Greenblatt MS, de Wind N. Assessment of functional effects of unclassified genetic variants. Hum Mutat. 2008 Nov;29(11):1314-1326. Pubmedid: 18951449. Pmcid: PMC2771414.
  • Barnholtz-Sloan J, Sloan AE, Land S, Kupsky W, Monteiro AN. Somatic alterations in brain tumors. Oncol Rep. 2008 Jul;20(1):203-210. Pubmedid: 18575738. Pmcid: PMC3933973.
  • Tischkowitz M, Hamel N, Carvalho MA, Birrane G, Soni A, van Beers EH, Joosse SA, Wong N, Novak D, Quenneville LA, Grist SA, Nederlof PM, Goldgar DE, Tavtigian SV, Monteiro AN, Ladias JA, Foulkes WD. Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: a multi-modal approach. Eur J Hum Genet. 2008 Jul;16(7):820-832. Pubmedid: 18285836. Pmcid: PMC3905962.
  • Easton DF, Deffenbaugh AM, Pruss D, Frye C, Wenstrup RJ, Allen-Brady K, Tavtigian SV, Monteiro AN, Iversen ES, Couch FJ, Goldgar DE. A Systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet. 2007 Nov;81(5):873-883. Pubmedid: 17924331.
  • Gomes MC, Costa MM, Borojevic R, Monteiro A, Vieira R, Koifman S, Koifman RJ, Li S, Royer R, Zhang S, Narod SA. Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil. Breast Cancer Res Treat. 2007 Jul;103(3):349-353. Pubmedid: 17063270.
  • Carvalho MA, Couch FJ, Monteiro AN. Functional assays for BRCA1 and BRCA2. Int J Biochem Cell B. 2007 Jun;39(2):298-310. Pubmedid: 16978908. Pmcid: PMC1862449.
  • Karchin R, Monteiro AN, Tavtigian SV, Carvalho MA, Sali A. Functional impact of missense variants in BRCA1 predicted by supervised learning. PLoS Comput Biol. 2007 Jun;3(2):e26. Pubmedid: 17305420. Pmcid: PMC1797820.
  • Carvalho MA, Monteiro AN. Correction: functional analysis of BRCA1 M1628V variant. J Med Genet. 2007 May;44(5):e78. Pubmedid: 17311832. Pmcid: PMC2597988.
  • Carvalho MA, Marsillac SM, Karchin R, Manoukian S, Grist S, Swaby RF, Urmenyi TP, Rondinelli E, Silva R, Gayol L, Baumbach L, Sutphen R, Pickard-Brzosowicz JL, Nathanson KL, Sali A, Goldgar D, Couch FJ, Radice P, Monteiro AN. Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis. Cancer Res. 2007 Feb;67(4):1494-1501. Pubmedid: 17308087. Pmcid: PMC2936786.
  • Monteiro AN. Involvement of the SH3 domain in Ca2+-mediated regulation of Src family kinases. Biochimie. 2006 Jul;88(7):905-911. Pubmedid: 16546311.
  • Gronwald J, Huzarski T, Byrski B, Medrek K, Menkiszak J, Monteiro A, Sun P, Lubinski J, Narod S. Cancer risks in first degree relatives of BRCA1 mutation carriers: effects of mutation and proband disease status. J Med Genet. 2006 Jul;43(5):424-428. Pubmedid: 16227521. Pmcid: PMC2564518.
  • Chiarini LB, Takiya CM, Borojevic R, Monteiro AN. Long-term culture of cholangiocytes from liver fibro-granulomatous lesions. Bmc Gastroenterol. 2006 Apr;6:13-13. Pubmedid: 16584555.
  • Monteiro A, Couch F. Cancer risk assessment at the atomic level. Cancer Res. 2006 Feb;66(4):1897-1899. Pubmedid: 16488985.
  • Rios-Doria J, Fay A, Velkova A, Monteiro A. DNA damage response: determining the fate of phosphorylated histone H2AX. Cancer Biol Ther. 2006 Feb;5(2):142-144. Pubmedid: 16552174.
  • Kaufman B, Laitman Y, Carvalho M, Edelman L, Menachem T, Zidan J, Monteiro A, Friedman E. The P1812A and P25T BRCA1 and the 5164del4 BRCA2 mutations: occurrence in high-risk non-Ashkenazi Jews. Genet Test. 2006;10(3):200-207. Pubmedid: 17020472.
  • Dapic V, Monteiro A. Functional implications of BRCA1 for early detection, prevention, and treatment of breast cancer. Crit Rev Eukaryot Gene Expr. 2006;16(3):233-252. Pubmedid: 17073553.
  • Billack B, Monteiro A. BRCA1 in breast and ovarian cancer predisposition. Cancer Lett. 2005 Oct;227(1):1-7. Pubmedid: 16051027.
  • Dapic V, Carvalho MA, Monteiro AN. Breast cancer susceptibility and the DNA damage response. Cancer Control. 2005 Apr;12(2):127-136. Pubmedid: 15855896.
  • Phelan CM, Dapic V, Tice B, Favis R, Kwan E, Barany F, Manoukian S, Radice P, van der Luijt RB, van Nesselrooij BP, Chenevix-Trench G, kConFab, Caldes T, de la Hoya M, Lindquist S, Tavtigian SV, Goldgar D, Borg A, Narod SA, Monteiro AN. Classification of BRCA1 missense variants of unknown clinical significance. J Med Genet. 2005 Feb;42(2):138-146. Pubmedid: 15689452.
  • Goldgar DE, Easton DF, Deffenbaugh AM, Monteiro AN, Tavtigian SV, Couch FJ. Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am J Hum Genet. 2004 Oct;75(4):535-544. Pubmedid: 15290653.
  • Billack B, Monteiro A. Methods to classify BRCA 1 variants of uncertain clinical significance: the more the merrier. Cancer Biol Ther. 2004;3(5):458-459. Pubmedid: 15118412.
  • Lubinski J, Phelan CM, Ghadirian P, Lynch HT, Garber J, Weber B, Tung N, Horsman D, Monteiro AN, Sun P, Narod SA. Cancer variation associated with the position of the mutation in the BRCA2 gene. Fam Cancer. 2004;3(1):1-10. Pubmedid: 15131399.
  • Geremias A, Carvalho M, Borojevic R, Monteiro A. TGF beta1 and PDGF AA override collagen type I inhibition of proliferation in human liver connective tissue cells. Bmc Gastroenterol. 2004;4(1):30-30. Pubmedid: 15579200.
  • Szabo CI, Worley T, Monteiro AN. Understanding germ-line mutations in BRCA1. Cancer Biol Ther. 2004;3(6):515-520. Pubmedid: 15254424.
  • Mirkovic N, Marti Renom MA, Weber BL, Sali A, Monteiro AN. Structure based assessment of missense mutations in human BRCA1: implications for breast and ovarian predisposition. Cancer Res. 2004;64(11):3790-3797. Pubmedid: 15172985.
  • Summy JM, Sudol M, Eck MJ, Monteiro AN, Gatesman A, Flynn DC. Specificity in signaling by c-Yes. Front Biosci. 2003 Jan;8:s185-s205. Pubmedid: 12456296.
  • Monteiro AN. BRCA1: the enigma of tissue-specific tumor development. Trends Genet. 2003;19(6):312-315. Pubmedid: 12801723.
  • Carvalho MA, Billack B, Chan E, Worley T, Cayanan C, Monteiro AN. Mutations in the BRCT domain confer temperature sensitivity to BRCA1 in transcription activation. Cancer Biology & Therapy. 2002;1(5):502-508. Pubmedid: 12496477.
  • Worley T, Vallon-Christersson J, Billack B, Borg A, Monteiro AN. A naturally occurring allele of BRCA1 coding for a temperature-sensitive mutant protein. Cancer Biol Ther. 2002;1(5):497-501. Pubmedid: 12496476.
  • Vallon Christersson, Cayanan C, Haraldsson K, Loman N, Bergthorsson JT, Brondum Nielsen K, Gerdes AM, Moller P, Kristoffersson U, Olsson H, Borg A, Monteiro AN. Functional analysis fo BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families. Hum Mol Genet. 2001;10(4):353-360. Pubmedid: 11157798.
  • Nadeau G, Boufaied N, Moisan A, Lemieux KM, Cayanan C, Monteiro AN, Gaudreau L. BRCA1 can stimulate gene transcription by a unique mechanism. Embo Rep. 2000 Sep;1(3):260-265. Pubmedid: 11256609. Pmcid: PMC1083733.
  • Hayes F, Cayanan C, Barilla D, Monteiro AN. Functional assay for BRCA1: mutagenesis of the COOH-terminal region reveals critical residue for transcription activation. Cancer Res. 2000;60(9):2411-2418. Pubmedid: 10811118.
  • Monteiro AN. BRCA1: exploring the links to transcription. Trends Biochem Sci. 2000;25(10):469-474. Pubmedid: 11050427.
  • Monteiro AN, Birge RB. A nuclear function for the tumor suppressor BRCA1. Histol Histopath. 2000;15(1):299-307. Pubmedid: 10668218.
  • Ouchi T, Monteiro AN, August A, Aaronson SA, Hanafusa H. BRCA1 regulates p53-dependent gene expression. Proc Natl Acad Sci U S A. 1998 Mar;95(5):2302-2306. Pubmedid: 9482880. Pmcid: PMC19327.
  • Monteiro AN, August A, Hanafusa H. Evidence for a transcriptional activation function of BRCA1 C-terminal region. Proc Natl Acad Sci U S A. 1996 Nov;93(24):13595-13599. Pubmedid: 8942979. Pmcid: PMC19361.
  • Tokiwa T, Kusaka Y, Muraoka A, Monteiro AN, Sato J. Effect of various factors and substrates on the growth of a human hepatoblastoma cell line, HuH-6 in a serum-free medium. Acta Med Okayama. 1989 Dec;43(6):359-362. Pubmedid: 2624143.
  • Permuth-Wey J, Lawrenson K, Shen HC, Velkova A, Tyrer JP, Chen Z, Lin HY, Ann Chen Y, Tsai YY, Qu X, Ramus SJ, Karevan R, Lee J, Lee N, Larson MC, Aben KK, Anton-Culver H, Antonenkova N, Antoniou AC, Armasu SM, Bacot F, Baglietto L, Bandera EV, Barnholtz-Sloan J, Beckmann MW, Birrer MJ, Bloom G, Bogdanova N, Brinton LA, Brooks-Wilson A, Brown R, Butzow R, Cai Q, Campbell I, Chang-Claude J, Chanock S, Chenevix-Trench G, Cheng JQ, Cicek MS, Coetzee GA, Cook LS, Couch FJ, Cramer DW, Cunningham JM, Dansonka-Mieszkowska A, Despierre E, Doherty JA, Dörk T, du Bois A, Dürst M, Easton DF, Eccles D, Edwards R, Ekici AB, Fasching PA, Fenstermacher DA, Flanagan JM, Garcia-Closas M, Gentry-Maharaj A, Giles GG, Glasspool RM, Gonzalez-Bosquet J, Goodman MT, Gore M, Górski B, Gronwald J, Hall P, Halle MK, Harter P, Heitz F, Hillemanns P, Hoatlin M, Høgdall CK, Høgdall E, Hosono S, Jakubowska A, Jensen A, Jim H, Kalli KR, Karlan BY, Kaye SB, Kelemen LE, Kiemeney LA, Kikkawa F, Konecny GE, Krakstad C, Krüger Kjaer S, Kupryjanczyk J, Lambrechts D, Lambrechts S, Lancaster JM, Le ND, Leminen A, Levine DA, Liang D, Kiong Lim B, Lin J, Lissowska J, Lu KH, Lubiński J, Lurie G, Massuger LF, Matsuo K, McGuire V, McLaughlin JR, Menon U, Modugno F, Moysich KB, Nakanishi T, Narod SA, Nedergaard L, Ness RB, Nevanlinna H, Nickels S, Noushmehr H, Odunsi K, Olson SH, Orlow I, Paul J, Pearce CL, Pejovic T, Pelttari LM, Pike MC, Poole EM, Raska P, Renner SP, Risch HA, Rodriguez-Rodriguez L, Anne Rossing ...
  • Bojesen SE, Pooley KA, Johnatty SE, Beesley J, Michailidou K, Tyrer JP, Edwards SL, Pickett HA, Shen HC, Smart CE, Hillman KM, Mai PL, Lawrenson K, Stutz MD, Lu Y, Karevan R, Woods N, Johnston RL, French JD, Chen X, Weischer M, Nielsen SF, Maranian MJ, Ghoussaini M, Ahmed S, Baynes C, Bolla MK, Wang Q, Dennis J, McGuffog L, Barrowdale D, Lee A, Healey S, Lush M, Tessier DC, Vincent D, Bacot F, Vergote I, Lambrechts S, Despierre E, Risch HA, González-Neira A, Rossing MA, Pita G, Doherty JA, Alvarez N, Larson MC, Fridley BL, Schoof N, Chang-Claude J, Cicek MS, Peto J, Kalli KR, Broeks A, Armasu SM, Schmidt MK, Braaf LM, Winterhoff B, Nevanlinna H, Konecny GE, Lambrechts D, Rogmann L, Guénel P, Teoman A, Milne RL, Garcia JJ, Cox A, Shridhar V, Burwinkel B, Marme F, Hein R, Sawyer EJ, Haiman CA, Wang-Gohrke S, Andrulis IL, Moysich KB, Hopper JL, Odunsi K, Lindblom A, Giles GG, Brenner H, Simard J, Lurie G, Fasching PA, Carney ME, Radice P, Wilkens LR, Swerdlow A, Goodman MT, Brauch H, Garcia-Closas M, Hillemanns P, Winqvist R, Dürst M, Devilee P, Runnebaum I, Jakubowska A, Lubinski J, Mannermaa A, Butzow R, Bogdanova NV, Dörk T, Pelttari LM, Zheng W, Leminen A, Anton-Culver H, Bunker CH, Kristensen V, Ness RB, Muir K, Edwards R, Meindl A, Heitz F, Matsuo K, du Bois A, Wu AH, Harter P, Teo SH, Schwaab I, Shu XO, Blot W, Hosono S, Kang D, Nakanishi T, Hartman M, Yatabe Y, Hamann U, Karlan BY, Sangrajrang S, Kjaer SK, Gaborieau V, Jensen A, Eccles D, Høgdall E, Shen CY, Brown J ...
  • Shen H, Fridley BL, Song H, Lawrenson K, Cunningham JM, Ramus SJ, Cicek MS, Tyrer J, Stram D, Larson MC, Köbel M, Ziogas A, Zheng W, Yang HP, Wu AH, Wozniak EL, Ling Woo Y, Winterhoff B, Wik E, Whittemore AS, Wentzensen N, Palmieri Weber R, Vitonis AF, Vincent D, Vierkant RA, Vergote I, Van Den Berg D, Van Altena AM, Tworoger SS, Thompson PJ, Tessier DC, Terry KL, Teo SH, Templeman C, Stram DO, Southey MC, Sieh W, Siddiqui N, Shvetsov YB, Shu XO, Shridhar V, Wang-Gohrke S, Severi G, Schwaab I, Salvesen HB, Rzepecka IK, Runnebaum IB, Anne Rossing M, Rodriguez-Rodriguez L, Risch HA, Renner SP, Poole EM, Pike MC, Phelan CM, Pelttari LM, Pejovic T, Paul J, Orlow I, Zawiah Omar S, Olson SH, Odunsi K, Nickels S, Nevanlinna H, Ness RB, Narod SA, Nakanishi T, Moysich KB, Monteiro AN, Moes-Sosnowska J, Modugno F, Menon U, McLaughlin JR, McGuire V, Matsuo K, Mat Adenan NA, Massuger LF, Lurie G, Lundvall L, Lubiński J, Lissowska J, Levine DA, Leminen A, Lee AW, Le ND, Lambrechts S, Lambrechts D, Kupryjanczyk J, Krakstad C, Konecny GE, Krüger Kjaer S, Kiemeney LA, Kelemen LE, Keeney GL, Karlan BY, Karevan R, Kalli KR, Kajiyama H, Ji BT, Jensen A, Jakubowska A, Iversen E, Hosono S, Høgdall CK, Høgdall E, Hoatlin M, Hillemanns P, Heitz F, Hein R, Harter P, Halle MK, Hall P, Gronwald J, Gore M, Goodman MT, Giles GG, Gentry-Maharaj A, Garcia-Closas M, Flanagan JM, Fasching PA, Ekici AB, Edwards R, Eccles D, Easton DF, Dürst M, du Bois A, Dörk T, Doherty JA, Despierre E, Dansonka-Mieszko ...
  • Pharoah PD, Tsai YY, Ramus SJ, Phelan CM, Goode EL, Lawrenson K, Buckley M, Fridley BL, Tyrer JP, Shen H, Weber R, Karevan R, Larson MC, Song H, Tessier DC, Bacot F, Vincent D, Cunningham JM, Dennis J, Dicks E, Aben KK, Anton-Culver H, Antonenkova N, Armasu SM, Baglietto L, Bandera EV, Beckmann MW, Birrer MJ, Bloom G, Bogdanova N, Brenton JD, Brinton LA, Brooks-Wilson A, Brown R, Butzow R, Campbell I, Carney ME, Carvalho RS, Chang-Claude J, Chen YA, Chen Z, Chow WH, Cicek MS, Coetzee G, Cook LS, Cramer DW, Cybulski C, Dansonka-Mieszkowska A, Despierre E, Doherty JA, Dörk T, du Bois A, Dürst M, Eccles D, Edwards R, Ekici AB, Fasching PA, Fenstermacher D, Flanagan J, Gao YT, Garcia-Closas M, Gentry-Maharaj A, Giles G, Gjyshi A, Gore M, Gronwald J, Guo Q, Halle MK, Harter P, Hein A, Heitz F, Hillemanns P, Hoatlin M, Høgdall E, Høgdall CK, Hosono S, Jakubowska A, Jensen A, Kalli KR, Karlan BY, Kelemen LE, Kiemeney LA, Kjaer SK, Konecny GE, Krakstad C, Kupryjanczyk J, Lambrechts D, Lambrechts S, Le ND, Lee N, Lee J, Leminen A, Lim BK, Lissowska J, Lubiński J, Lundvall L, Lurie G, Massuger LF, Matsuo K, McGuire V, McLaughlin JR, Menon U, Modugno F, Moysich KB, Nakanishi T, Narod SA, Ness RB, Nevanlinna H, Nickels S, Noushmehr H, Odunsi K, Olson S, Orlow I, Paul J, Pejovic T, Pelttari LM, Permuth-Wey J, Pike MC, Poole EM, Qu X, Risch HA, Rodriguez-Rodriguez L, Rossing MA, Rudolph A, Runnebaum I, Rzepecka IK, Salvesen HB, Schwaab I, Severi G, Shen H, Shridhar V, Shu XO, Sieh W, ...
  • Monteiro A. Participation of BRCA1 in the DNA repair response...via transcription. Cancer Biol Ther. 1(2):187-188. Pubmedid: 12212615.
TOOLS:   Font Size small font resizer separator font resizer separator big font resizer
 |  Site Map  |  Privacy Policy  |  Terms and Conditions